GO
Loading...

Lightning Round: Zynga, Bob Evans Farms & More

Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

Solazyme (SZYM): It doesn't have a great balance sheet and it doesn't make a lot of money, said Cramer. Don't buy.

Retrophin (RTRX): I think this is a froth stock, said Cramer. It's moved up too much.

Chelsea Therapeutics (CHTP): I like this as a spec, said Cramer. It's a play on Rheumatoid Arthritis.


Getty Images

InvenSense (INVN): It's a play on motion detection, said Cramer. It's been bid up but now it needs big contracts, said Cramer. Without big contracts I think it gives up the ghost.

Zynga (ZNGA): I don't think it's done going up, said Cramer. I think it can still go higher.

Bob Evans Farms (BOBE): I think it's a great company, said Cramer, but it had a terrible quarter. However, I wouldn't sell down here.



Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the "Mad Money" website? madcap@cnbc.com

Symbol
Price
 
Change
%Change
SOLAZYME
---
3CH
---
INVENSENSE
---
ZYGNA
---
BOBE
---

Featured

Contact Mad Money

  • Showtimes

    U.S.
    Monday - Friday 6p ET
    Australia
    Saturday 8a, 1p, 7p SYD
    Sunday 12a, 1a, 8a, 7p SYD
    New Zealand
    Saturday 10a, 3p, 9p NZ
    Sunday 2a, 3a, 10a, 9p NZ
  • Jim Cramer is host of CNBC's "Mad Money" and co-anchor of the 9 a.m. ET hour of CNBC's "Squawk on the Street."

Mad Money Features

  • Grab the latest CNBC gear from the NBCUniversal Store!

  • Get a behind-the-scenes look at how Cramer formulates his investment advice. "Inside the Madness" is a column, which features e-mails and more with Cramer and his researcher Nicole Urken.

  • You’ve always wanted to hit the “Hallelujah!” button. Here’s your chance.

Cramer's New Book